What is the 13F Pro Quality Score for ASTH?

13F Pro ranks Astrana Health, Inc. (ASTH) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ASTH's current score at https://13fpro.ai/research/ASTH (free sign-up required for the full ranking).

Which hedge funds own the most ASTH stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ASTH include BlackRock,, VANGUARD PORTFOLIO MANAGEMENT, 325 CAPITAL. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/ASTH as soon as new 13F filings post.

Where does 13F Pro source ASTH data?

All Astrana Health, Inc. fundamentals and ownership data come directly from SEC EDGAR. Astrana Health, Inc. files with the SEC under CIK 1083446. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ASTH in?

Astrana Health, Inc. (ASTH) is classified in the Technology sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/technology.

How often is ASTH research updated on 13F Pro?

ASTH's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Astrana Health, Inc.(ASTH)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Technology →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1083446 ASTH stock profile & AI dashboard →

13F Pro Quality Score

56.8/100

Rank #1,082 of 2,879 stocksTOP 50%

View Technology peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

89.7/100

Profitability

32.8/100

Balance Sheet

47.9/100

Earnings Quality

13.8/100

Free Cash Flow

51.6/100

Institutional Flow

79.6/100

Revenue Scale

67.7/100

Dilution Risk

52.2/100

ASTH Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Astrana Health, Inc. (ASTH), a Technology sector company. 13F Pro's AI-powered ranking engine scores ASTH at 56.8/100 on a 32-signal composite quality model, placing it at rank #1,082 of 2,879 stocks — the top half of the AI-ranked universe. ASTH scores in the top quartile across revenue growth (89.7), institutional flow (79.6). Areas of concern include earnings quality (13.8) and profitability (32.8), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q1 2026), Astrana Health, Inc. reports quarterly revenue of $965.1M, net income of $14.4M, an operating margin of 3.0%. Top institutional holders of ASTH by reported 13-F value include BlackRock,, VANGUARD PORTFOLIO MANAGEMENT, 325 CAPITAL, based on the most recent SEC filings. ASTH trades on the Nasdaq exchange and files with the SEC under CIK 1083446. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ASTH daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Astrana Health, Inc. directly from SEC EDGAR. Astrana Health, Inc.'s 13F Pro composite quality score has ranged between 8 and 79 since 2024, currently 56.8 — a stable long-term trajectory across 43 quarterly and live scoring snapshots.

Revenue

Q1 2026

$965.1M

Net Income

Q1 2026

$14.4M

Free Cash Flow

Q1 2026

$64.1M

Operating Margin

Q1 2026

3.0%

ROIC

Q1 2026

1.6%

D/E Ratio

Q1 2026

1.28

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+56.4% YoY

$3.18BFY 2025

FY22 $1.14BFY23 $1.39BFY24 $2.03BFY25 $3.18B

Net Income

-44.4% YoY

$24.0MFY 2025

FY22 $45.2MFY23 $58.0MFY24 $43.1MFY25 $24.0M

Operating Income

-12.1% YoY

$78.5MFY 2025

FY22 $104.3MFY23 $84.6MFY24 $89.3MFY25 $78.5M

EPS (Diluted)

-48.9% YoY

$0.46FY 2025

FY22 $0.01FY23 $0.01FY24 $0.90FY25 $0.46

Total Assets

+63.8% YoY

$2.22BFY 2025

FY22 $966.2MFY23 $933.4MFY24 $1.35BFY25 $2.22B

Total Debt

+139.0% YoY

$1.04BFY 2025

FY22 $204.0MFY23 $278.4MFY24 $434.7MFY25 $1.04B

Op. Cash Flow

+119.5% YoY

$114.6MFY 2025

FY22 $82.1MFY23 $68.2MFY24 $52.2MFY25 $114.6M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2017	FY 2016
Revenue	$3.18B +56.4%	$2.03B +46.7%	$1.39B +21.2%	$1.14B +221.1%	$356.4M +16.5%	$305.9M
Net Income	$24.0M -44.4%	$43.1M -25.6%	$58.0M +28.4%	$45.2M +75.1%	$25.8M +125.3%	$11.5M
Operating Income	$78.5M -12.1%	$89.3M +5.6%	$84.6M -18.8%	$104.3M +196.7%	$35.1M +200.7%	$11.7M
EPS (Diluted)	$0.46 -48.9%	$0.90 +6616.4%	$0.01 +30.1%	$0.01 +9.6%	$0.01 +118.6%	$0.00
Total Assets	$2.22B +63.8%	$1.35B +45.2%	$933.4M -3.4%	$966.2M +96.9%	$490.6M +2823.1%	$16.8M
Total Debt	$1.04B +139.0%	$434.7M +56.1%	$278.4M +36.5%	$204.0M	—	—
Operating Cash Flow	$114.6M +119.5%	$52.2M -23.5%	$68.2M -16.9%	$82.1M +58.4%	$51.8M +136.5%	$21.9M

AI Insight: ASTH Ratio Trends

Profitability collapsed from 7.4% operating margins in early 2024 to just 2.5% TTM, while leverage doubled to 1.28x debt-to-equity.

• Operating margin deteriorated from 7.4% in Q1 2024 to 2.5% TTM, dropping 490 basis points over two years.

• Net profit margin fell from 3.7% in Q1 2024 to 0.7% TTM, with Q4 2024 posting a -1.0% loss.

• ROIC declined from 11.6% in Q1 2024 to 4.3% TTM, though Q1 2026 showed improvement to 6.2%.

• Debt-to-equity ratio more than doubled from 0.60x in Q1 2024 to 1.28x currently.

⚠ Q1 2026 operating margin improved to 3.0% from 1.9% in Q4 2025, signaling potential stabilization.

⚠ ROE recovered to 7.2% in Q1 2026 from near-zero levels in Q2-Q3 2025, but remains below historical peaks.

Get alerted when ASTH's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Astrana Health, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ASTH

BlackRock, Inc.
$151.1M6,163,727 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$55.8M2,276,806 sh
325 CAPITAL LLC
$45.1M1,839,076 sh
VANGUARD CAPITAL MANAGEMENT LLC
$41.9M1,710,262 sh
STATE STREET CORP
$40.5M1,650,490 sh
DIMENSIONAL FUND ADVISORS LP
$33.5M1,368,079 sh
WELLINGTON MANAGEMENT GROUP LLP
$32.9M1,341,824 sh
GEODE CAPITAL MANAGEMENT, LLC
$25.5M1,038,085 sh
683 Capital Management, LLC
$17.2M700,000 sh
CHARLES SCHWAB INVESTMENT MANAGEMENT INC
$15.8M644,171 sh

Fund	Value	Shares
BlackRock, Inc.	$151.1M	6,163,727
VANGUARD PORTFOLIO MANAGEMENT LLC	$55.8M	2,276,806
325 CAPITAL LLC	$45.1M	1,839,076
VANGUARD CAPITAL MANAGEMENT LLC	$41.9M	1,710,262
STATE STREET CORP	$40.5M	1,650,490
DIMENSIONAL FUND ADVISORS LP	$33.5M	1,368,079
WELLINGTON MANAGEMENT GROUP LLP	$32.9M	1,341,824
GEODE CAPITAL MANAGEMENT, LLC	$25.5M	1,038,085
683 Capital Management, LLC	$17.2M	700,000
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	$15.8M	644,171

More Technology Companies

View all Technology →

AGILENT TECHNOLOGIES, INC.

AAOI

APPLIED OPTOELECTRONICS, INC.

AAPL

Apple Inc.

ABNB

Airbnb, Inc.

ACCL

Acco Group Holdings Ltd

ACCS

ACCESS Newswire Inc.

ACFN

ACORN ENERGY, INC.

ACIW

ACI WORLDWIDE, INC.

Put ASTH on your watchlist

Track score changes the day Astrana Health, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ASTH a good stock to buy?

13F Pro's AI-powered analysis of Astrana Health, Inc. (ASTH) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Technology sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ASTH are available on the ASTH stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ASTH?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ASTH. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Astrana Health, Inc.'s investment landscape.